Prot #CC-486-AML-001: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Subjects with Acute Myeloid Leukemia in

Project: Research project

Project Details

StatusFinished
Effective start/end date9/13/139/13/19

Funding

  • Celgene Corporation (Prot #CC-486-AML-001)